Lung Transplantation

Primer on Transplantation: Third Edition

Volumn , Issue , 2011, Pages 205-237

  Spahr, Jonathan E ^a   Meyer, Keith C ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Grading of acute rejection and bronchiolitis obliterans syndrome; Indications for disease specific patient referral and transplantation; Indications for lung transplantation categories of obstructive, restrictive, suppurative and vascular pulmonary diseases; Infection, a constant concern in perioperative period arising from aspiration, surgical sites or nosocomial infections; Lung transplantation absolute and relative contraindications; Lung transplantation, and allotransplantation of human lung performed first by Dr james hardy at university of mississippi; Pediatric transplantation matching and prioritization; PGD, airway complications and refractory acute rejection progressive BOS, irreversible allograft dysfunction and respiratory failure after lung transplantation; Re transplantation for bos, and survival rates long term survival rates for primary lung transplantation; Timing of referral for patients with advanced cf lung disease a challenge to referring physicians

Indexed keywords

EID: 84878276415     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444391770.ch9     Document Type: Chapter

References (111)

1. Aboyoun CL, Tamm M, Chhajed PN, et al. Diagnostic value of follow-up transbronchial lung biopsy after lung rejection. Am J Respir Crit Care Med 2001; 164: 460-3.
2. Aigner C, Jaksch P, Taghavi S, et al. Pulmonary retransplantation: is it worth the effort? A long-term analysis of 46 cases. J Heart Lung Transplant 2008; 27: 60-5.
3. Amital A, Shitrit D, Raviv Y, et al. Development of malignancy following lung transplantation. Transplantation 2006; 81: 547-551.
4. Angel LF, Levine DJ, Restrepo MI, et al. Impact of lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med 2006; 174: 710-16.
5. Anonymous. Lung Allocation Score System for Transplant Professionals. United Network for Organ Sharing, 2005. Available at: www.unos.org.
6. Arcasoy SM, Hersh C, Christie JD, et al. Bronchogenic carcinoma complicating lung transplantation. J Heart Lung Transplant 2001; 20: 1044-53.
7. Aris RM, Gilligan PH, Neuringer IP, Gott KK, Rea J, Yankaskas JR. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155: 1699-1704.
8. Aris RM, Neuringer IP, Weiner MA, et al. Severe osteoporosis before and after lung transplantation. Chest 1996; 109: 1176-83.
9. Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164: 2102-6.
10. Bando, K, Armitage, JM, Paradis, IL, et al. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1994; 108: 1056-65.
11. Bankier AA, Muylem AV, Knoop C, Estenne M, Gevenois PA. BOS in heart-lung transplant recipients: diagnosis with expiratory CT. Radiology 2001; 218: 533-9.
12. Barraclough K, Menahem SA, Bailey M, Thomson NM. Predictors of decline in renal function after lung transplantation. J Heart Lung Transplant 2006; 25: 1431-5.
13. Bartz R, Will L, Welter D, Love R, Meyer K. Outcome following lung transplantation for mechanically ventilated patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163: A335.
14. Benden C, Aurora P, Curry J, Whitmore P, Priestley L, Elliott MJ. High prevalence of gastroesophageal reflux in children after lung transplantation. Pediatr Pulmonol 2005; 40: 68-71.
15. Blondeau K, Mertens V, Vanaudenaerde BA, et al. Acid, non-acid GER and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J 2007; 37: 625-30.
16. Boehler A, Estenne. Post-transplant bronchiolitis obliterans. Eur Respir J 2003; 22: 1007-18.
17. Botha P, Fisher AJ, Dark JH. Marginal lung donors: a diminishing margin of safety? Transplantation 2006; 82: 1273-9.
18. Bowdish ME, Arcasoy SM, Wilt JS, et al. Surrogate markers and risk factors for chronic lung allograft dysfunction. Am J Transplant 2004; 4: 1171-8.
19. Braith RW, Conner JA, Fulton MN, et al. Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. J Heart Lung Transplant 2007; 26: 32-137.
20. Canales M, Youssef P, Spong R, et al. Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. Am J Transplant 2006; 6: 2157-63.
21. Caplan-Shaw CE, Arcasoy SM, Shane E, et al. Osteoporosis in diffuse parenchymal lung disease. Chest 2006; 129: 140-6.
22. Chakinala MM, Ritter J, Gage BF, et al. Yield of surveillance bronchoscopy for acute rejection and lymphocytic bronchitis/bronchiolitis after lung transplantation. J Heart Lung Transplant 2004; 23: 1396-404.
23. Chamberlain D, Maurer J, Chaparro C, Idolor L. Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 1994; 13: 963-71.
24. Chatila WM, Furukawa S, Gaughan JP, Criner, GJ. Respiratory failure after lung transplantation. Chest 2003; 123: 165-73.
25. Choong CK, Meyers BF. Quality of life after lung transplantation. Thorac Surg Clin 2004; 14: 385-407.
26. Christie JD, Bavaria JE, Palevsky HI, et al. Primary graft failure following lung transplantation. Chest 1998; 114: 51-60.
27. Christie JD, KotloffRM, Ahya VN, et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171: 1312-16.
28. Cooper JD, Billingham M, Egan T, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993; 12: 713-16.
29. Corris P, Glanville A, McNeil K, et al. One year analysis of an ongoing international randomized study of mycophenolate mofetil (MMF) vs azathioprine (AZA) in lung transplantation. J Heart Lung Transplant 2001; 20: 149-50.
30. Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175: 507-13.
31. deJong PA, Dodd JD, Coxson HO, et al. Bronchiolitis obliterans following lung transplantation: early detection using computed tomographic scanning. Thorax 2006; 61: 799-804.
32. Dellon ES, Morgan DR, Mohanty SP, Davis K, Aris RM. High incidence of gastric bezoars in cystic fibrosis patients after lung transplantation. Transplantation 2006; 81: 1141-6.
33. DeMeo DL, Ginns LC. Clinical status of lung transplantation. Transplantation 2001; 72: 1713-24.
34. Efrati O, Kremer MR, Barak A, et al. Improved survival following lung transplantation with long-term use of bilevel positive pressure ventilation in cystic fibrosis. Lung 2007; 185: 73-9.
35. Egan TM. Non-heart-beating donors in thoracic transplantation. J Heart Lung Transplant 2004; 23: 3-10.
36. Egan TM, Edwards LB, Coke MA, et al. Lung allocation in the United States. In: Lynch JP III, Ross DJ (eds), Lung Biology in Health and Disease, Vol 217. Lung and Heart-Lung Transplantation New York, Taylor & Francis, 2006: 285-300.
37. Elizur A, Sweet SC, Huddleston CB, et al. Pre-transplantation mechanical ventilation increases short-term morbidity and mortality in pediatric patients with cystic fibrosis. J Heart Lung Transplant 2007; 26: 127-31.
38. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: 297-310.
39. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis: impact after isolated lung transplantation. Am Rev Respir Dis 1993; 147: 1017-23.
40. Fischer S, Bohn D, Rycus P, et al. Extracorporeal membrane oxygenation for primary graft dysfunction at lung transplantation: analysis of the Extracorporeal Life Support Organization (ELSO) registry. J Heart Lung Transplant 2007; 26: 472-7.
41. Flume PA, Egan TM, Paradowski LJ, Detterbeck FC, Thompson JT, Yankaskas JR. Infectious complications of lung transplantation: impact of cystic fibrosis. Am J Respir Crit Care Med 1994; 149: 1601-7.
42. Gammie JS, Keenan RJ, Pham SM, et al. Single-versus double-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg 1998; 115: 397.
43. George I, Xydas S, Topkara VK, et al. Clinical indication for use and outcomes after inhaled nitric oxide therapy. Ann Thorac Surg 2006; 82: 2161-9.
44. Gerbase MW, Spiliopoulos A, Rochat T, Archinard M, Nicod LP. Health-related quality of life following single or bilateral lung transplantation: a 7-year comparison to functional outcome. Chest 2005; 128: 1371-8.
45. Glanville AR. The role of bronchoscopic surveillance monitoring in the care of lung transplant recipients. Semin Respir Crit Care Med 2006; 27: 480-91.
46. Glanville AR, Estenne M. Indications, patient selection and timing of referral for lung transplantation. Eur Respir J 2003; 22: 845-52.
47. Glanville AR, Aboyoun CL, Morton JM, et al. Cyclosporine C2 target levels and acute cellular rejection after lung transplantation. J Heart Lung Transplant 2006; 25: 928-34.
48. Groetzner J, Kur F, Spelsberg F, et al., Munich Lung Transplant Group. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004; 23: 632-8.
49. Hadijiliadis D, Madill J, Chaparro C, et al. Incidence and prevalence of diabetes mellitus in patients with cystic fibrosis undergoing lung transplantation before and after lung transplantation. Clin Transplant 2005; 19: 773-8.
50. Hadjiliadis D, Angel LF. Controversies in lung transplantation: Are two lungs better than one? Semin Respir Crit Care Med 2007; 27: 561-6.
51. Hardy JD, Webb WR, Dalton ML, Walker GR. Lung homotransplantation in man: report of the initial case. JAMA 1963; 186: 1065-74.
52. Helmi M, Welter D, Cornwell RD, Love RB, Meyer KC. Tracheobronchial aspergillosis in lung transplant recipients with cystic fibrosis; risk factors and outcome comparison to other transplant recipients. Chest 2003; 123: 800-8.
53. Horning NR, Lynch JP, Sundaresan SR, Patterson GA, Trulock EP. Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant 1998; 17: 761-7.
54. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008-16.
55. Iacono AT, Johnson BA, Grgurich B, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med 2006; 354: 141-50.
56. Ishani A, Erturk S, Hertz MI, Matas AJ, Savik K, Rosenberg ME. Predictors of renal function following lung or heart-lung transplantation. Kidney Int 2002; 61: 2228-34.
57. Kahan ES, Petersen G, Gaughan JP, Criner GJ. High incidence of venous thromboembolic events in lung transplant recipients. J Heart Lung Transplant 2007; 26: 339-44.
58. Kaneda H, Waddell TK, de Perrot M, et al. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant 2006; 6: 544-51.
59. Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med 2008; 177: 114-20.
60. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. New Engl J Med 1992; 326: 1187-91.
61. Knoop C, Thiry P, Saint-Marcoux F, Rousseau A, Marquet P, Estenne M. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. Am J Transplant 2005; 5: 1477-82.
62. Knoop C, Vervier I, Thiry P, et al. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation 2003; 76: 683-8.
63. KotloffRM, Ahya VN. Medical complications of lung transplantation. Eur Respir J 2004; 23: 334-42.
64. Kroshus TJ, Kshettry VR, Savik K, John R, Hertz MI, Bolman RM III. Risk factors for the development of bron chiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997; 114: 195-202.
65. Lama VN, Flaherty KR, Toews GB, et al. Prognostic value of desaturation during 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 1084-90.
66. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: A report of 24 cases observed at a single center. J Clin Oncol 1995; 13: 961-8.
67. Lee E-S, Gotway MB, Reddy GP, Golden JA, Keith FM, Webb WR. Early bronchiolitis obliterans following lung transplantation: accuracy of expiratory thin-section CT for diagnosis. Radiology 2000; 216: 472-7.
68. Levy G, Thervet E, Lake J, et al. Patient management by Neoral C2 monitoring: an international consensus statement. Transplantation 2002; 73: S12-18.
69. Levy RD, Ernst P, Levine SM, et al. Exercise performance after lung transplantation. J Heart Lung Transplant 1993; 12: 27-33.
70. Lu BS, Garrity ER Jr, Bhorade SM. Immunosuppressive drugs: cyclosporine, tacrolimus, sirolimus, azathioprine, mycophenolate mofetil, and corticosteroids. In: Lynch JP III, Ross DJ (eds), Lung Biology in Health and Disease, Vol 217. Lung and Heart-Lung Transplantation. New York: Taylor & Francis, 2006: 363-99.
71. McAnally KJ, Valentine VG, LaPlace SG, McFadden PM, Seoane L, Taylor DE. Effect of pre-transplantation prednisone on survival after lung transplantation. J Heart Lung Transplant 2006; 25: 67-74.
72. Martinez, FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2004; 142: 963-7.
73. Maurer JR, Frost AE, Estenne M, et al. International Guidelines for the Selection of Lung Transplant Candidates. J Heart Lung Transplant 1998; 17: 703-9.
74. Maurer JR. Metabolic bone disease in lung transplant recipients. In: Lynch JP III, Ross DJ (eds), Lung Biology in Health and Disease, Vol 217. Lung and Heart-Lung Transplantation. New York: Taylor & Francis, 2006: 895-9.
75. Mayer-Hamblett N, Rosenfeld M, Emerson J, et al. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166: 1550-5.
76. Meade MO, Granton JT, Matte-Martyn A, et al. A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 2003; 167: 1483-9.
77. Meyer K. Allogeneic recognition and immune tolerance in lung transplantation. In: Lynch JP III, Ross DJ (eds), Lung Biology in Health and Disease, Vol 217. Lung and Heart-Lung Transplantation. New York: Taylor & Francis, 2006: 47-60.
78. Moro J, Almenar L, Martinez-Dolz L, et al. mTOR inhibitors: do they help preserve renal function? Transplant Proc 2007; 39: 2135-7.
79. Orens JB, Boehler A, de Perrot M, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003; 22: 1183-200.
80. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update-a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-55.
81. Palmer SM, Miralles AP, Howell DN, et al. Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. Chest 2000; 118: 1214-7.
82. Patterson GA. Historical development of pulmonary transplantation. Semin Respir Crit Care Med 1996; 17: 103-7.
83. Pierre F, Keshavjee S. Lung transplantation: donor and recipient critical care aspects. Curr Opin Crit Care 2005; 11: 339-44.
84. Pilcher DV, Scheinkestel CD, Snell GI, et al. A high central venous pressure is associated with prolonged mechanical ventilation and increased mortality following lung transplantation. J Thoracic Cardiovasc Surg 2005; 129: 912-8.
85. Ramalingam P, Rybicki L, Smith MD, et al. Posttransplant lymphoproliferative disorders in lung transplant patients: the Cleveland Clinic experience. Mod Pathol 2002; 15: 647-56.
86. Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124: 1242-9.
87. Ross DJ, Waters PF, Levine M, Kramer M, Ruzevich S, Kass RM. Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant 1998; 17: 768-74.
88. Shumway, SJ, Hertz, MI, Petty, MG, Bolman, RM. Liberalization of donor criteria in lung and heart-lung transplantation. Ann Thorac Surg 1994; 57: 92-5.
89. Smeritschnig B, Jaksch P, Kocher A, et al. Quality of life after lung transplantation: a cross-sectional study. J Heart Lung Transplant 2005; 24: 474-80.
90. Snyder LD, Palmer SM. Immune mechanisms of lung allograft rejection. Semin Respir Crit Care Med 2006; 27: 534-43.
91. Starnes VA, Barr ML, Cohen RG. Lobar transplantation: indications, technique and outcome. J Thorac Cardiovasc Surg 1994; 108: 403-10.
92. Starnes VA, Bowdish ME, Woo MS, et al. A decade of living lobar lung transplantation: recipient outcomes. J Thorac Cardiovasc Surg 2004; 127: 114-22.
93. Studer SM, Levy RD, McNeil K, Orens JB. Lung transplant outcomes: a review of survival, graft function, physiology, health-related quality of life and cost-effectiveness. Eur Respir J 2004; 24: 674-85.
94. Swanson SJ, Mentzer SJ, Reilly JJ, et al. Surveillance transbronchial lung biopsies: implication for survival after lung transplantation. J Thorac Cardiovasc Surg 2000; 119: 27-37.
95. Thabut G, Mal H, Cerrina J, Dartevelle P, et al. Graft ischemic time and outcome of lung transplantation. Am J Respir Crit Care Med 2005; 171: 786-91.
96. Thabut G, Vinatier I, Stern JB, et al. Primary graft failure following lung transplantation: Predictive factors of mortality. Chest 2002; 121: 1876-82.
97. Trulock EP, Ettinger NA, Brunt EM, Pasque MK, Kaiser LR, Cooper JD. The role of transbronchial lung biopsy in the treatment of lung transplant recipients. An analysis of 200 consecutive procedures. Chest 1992; 102: 1049-54.
98. Trulock, EP. Lung Transplantation. Am J Respir Crit Care Med 1997; 155: 789-815.
99. Van De Wauwer C, Van Raemdonck D, Verleden GM, et al. Risk factors for airway complications within the first year after lung transplantation. Eur J Cardiothorac Surg 2007; 31: 703-10.
100. Venuta F, De Giacomo T, Rendina EA, et al. Recovery of chronic renal impairment with sirolimus after lung transplantation. Ann Thorac Surg 2004; 78: 1940-3.
101. Verleden GM, Dupont LJ. Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2004; 77: 1465-7.
102. Verschuuren EA, Stevens S, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of post-transplant lymphoproliferative disease in lung transplant patients. J Heart Lung Transplant 2001; 20: 199-200.
103. Weigt SS, Lynch JP III, Langer LR, et al. Lymphoproliferative disorders complicating solid organ transplantation. In: Lynch JP III, Ross DJ (eds), Lung Biology in Health and Disease, Vol 217. Lung and Heart-Lung Transplantation. New York: Taylor & Francis, 2006: 901-34.
104. Wigfield CH, Lindsey JD, Steffens TG, et al. Early institution of extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation improved outcome. J Heart Lung Transplant 2007; 26: 331-8.
105. Williams TJ, Patterson GA, McClean PA, Zamel N, Maurer JR. Maximal exercise testing in single and double lung transplant recipients. Am Rev Respir Dis 1992; 145: 101-5.
106. Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. N Engl J Med 2004; 351: 2730-9.
107. Yates B, Murphy DM, Forrest IA, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005; 172: 772-5.
108. Young LR, Hadjiliadis D, David D, et al. Lung transplantation exacerbates gastroesophageal reflux disease. Chest 2003; 124: 1689-93.
109. Yousem SA, Berry GJ, Cagle PT, et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996; 15: 1-15.
110. Zamora MR, Davis RD, Leonard C, et al. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005; 80: 157-63.
111. Zuckermann A, Klepetko W, Birsan T, et al. Comparison between mycophenolate mofetil-and azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant 1999; 18: 432-40.